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Neuropeptide W (NPW), which was first isolated from the porcine hypothalamus,
exists in two forms, consisting of 23 (NPW23) or 30 (NPW30) amino acids. These
neuropeptides bind to one of two NPW receptors, either NPBWR1 (otherwise known
as GPR7) or NPBWR2 (GPR8), which belong to the G protein-coupled receptor
family. GPR7 is expressed in the brain and peripheral organs of both humans and
rodents, whereas GPR8 is not found in rodents. GPR7 mRNA in rodents is widely
expressed in several hypothalamic regions, including the paraventricular, supraoptic,
ventromedial, dorsomedial, suprachiasmatic, and arcuate nuclei. These observations
suggest that GPR7 plays a crucial role in the modulation of neuroendocrine function. The
intracerebroventricular infusion of NPW has been shown to suppress food intake and body
weight and to increase both heat production and body temperature, suggesting that NPW
functions as an endogenous catabolic signaling molecule. Here we summarize our current
understanding of the distribution and function of NPW in the brain.
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INTRODUCTION
In 1995, O’Dowd et al. (1995) used oligonucleotides based on
the opioid receptor as well as the structurally related somato-
statin receptor to identify two genes, GPR7 (NPBWR1) andGPR8
(NPBWR2), which were predicted to encode two G protein-
coupled receptors (GPCRs) in the human brain. NPBWR1mRNA
expression is demonstrated in the human and rodent brain,
whereas the NPBWR2 gene is detected in the human and rabbit,
but not the rodent, brain (Lee et al., 1999). In 2002, Shimomura
et al. (2002) identified the endogenous ligand for NPBWR1-
2 by exposing Chinese Hamster Ovary (CHO) cells to porcine
hypothalamic extracts with monitoring changes in the level of
cAMP. Moreover, when cell lines that expressed either NPBWR1
or NPBWR2 were incubated with the hypothalamic extracts,
forskolin-induced cAMP production was inhibited. These recep-
tors were coupled to the heterotrimeric Gi protein-mediated
receptors (Shimomura et al., 2002). Further structural analysis
of the ligands responsible for the inhibition of cAMP produc-
tion led to the identification of a novel peptide, neuropeptide W
(NPW). Shimomura et al. identified mature peptide sequences of
both 23 and 30 residues from porcine, rat, and human prepro
NPW (Figure 1). NPW is named after the tryptophan residues
appearing at both its N- and C-terminals in its two mature forms:
NPW30 (the 30 amino acid form) and NPW23 (consisting of 23
amino acids, which are identical to the N-terminal 23 residues
of NPW30) (Figure 1). At the same time, the human gene for
NPW was identified by Tanaka et al. (2003), who also cloned the
mouse gene and reported restricted expression in specific neurons
in the mid-brain and brainstem. Similarly, Brezillon et al. (2003)
identified the shorter 23 amino acid form of the peptide, which
they termed L8 that was derived by proteolytic processing from
the longer peptide. The prepropeptide was designated prepro-G
protein-coupled receptor 8 ligand.
DISTRIBUTION OF NPW
Based on RT-PCR analysis, Brezillon et al. (2003) have reported
that NPW mRNA is highly expressed in the substantia nigra
and spinal cord, and moderately expressed in the hippocam-
pus, amygdala, hypothalamus corpus callosum, cerebellum, and
dorsal root ganglia in the human central nervous system. In
rodents, in situ hybridization histochemistry has revealed that
NPWmRNA is expressed in a few restricted brain regions, includ-
ing the rat periaqueductal gray (PAG), Edinger-Westphal nucleus
(EW), and dorsal raphe nucleus (Baker et al., 2003; Tanaka et al.,
2003; Kitamura et al., 2006), while Kitamura et al. (2006) have
reported that it is confined to specific nuclei in the rat midbrain
and brainstem. However, based on RT-PCR analysis, we have
reported that NPW mRNA is expressed in the rat hypothalamic
paraventricular nucleus (PVN), ventromedial nucleus (VMH),
arcuate nucleus (ARC), and lateral hypothalamus (LH) (Takenoya
et al., 2010), with another study also reporting the expres-
sion of NPW in various areas of the rat brain (Dun et al.,
2003). Immunohistochemical studies have shown that NPW-like
immunoreactive (NPW-LI) neuronal cell bodies mainly observed
in the hypothalamic areas, ARC and posterior pituitary gland,
with a lower level in the PVN. Interestingly, NPW-LI cells appear
to be more numerous in the male than the female hypotha-
lamus (Dun et al., 2003). In another study, Kitamura et al.
(2006) reported a heavy localization of NPW-LI cell bodies in
the midbrain, including the PAG and EW. Furthermore, we first
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FIGURE 1 | Sequence comparison of NPW-23 and NPW-30. Human, porcine rat and mouse NPW-23 and NPW-30 sequences are aligned. A gray area
indicates a common amino acid sequence of both NPW-23 and NPW-30.
identified the presence of NPW-LI cell bodies and their processes
in the PVN, VMH, and amygdala at the electron microscopic
level (Takenoya et al., 2009). Moreover, NPW-LI nerve fibers
were abundantly distributed in the midbrain and limbic system,
including the CeA and BST, suggests that NPWmay play a role in
the regulation of fear and anxiety as well as in feeding behavior
(Dun et al., 2003; Hondo et al., 2008; Takenoya et al., 2009, 2010).
In the peripheral tissues, NPW is expressed in the trachea, as
well as in lymphoblastic leukemia in the fetal kidney and colorec-
tal adenocarcinoma (Brezillon et al., 2003). Rat adrenocortical
cells are also shown to produce NPW (Hondo et al., 2008), as
have noradrenalin-containing cells in the rat adrenal medulla
(Seki et al., 2008) and gastric antral G cells in rats and mice
(Mondal et al., 2006), with expression of NPW in the rat stomach
mucosa being regulated by nutritional status, glucocorticoids, and
thyroid hormones (Caminos et al., 2008). Hochol et al. (2006)
have reported expression of NPW in the thyroid and parathy-
roid glands, pancreatic islets, adrenal glands, ovary, and testis
of the rat, while Rucinski et al. (2007) have demonstrated NPW
immunoreactivity in all of the cells of the pancreatic islets, includ-
ing the A, B, and D cells, and PP cells. In contrast, Dezaki et al.
(2008) found NPW immunoreactivity in the B cells, but not in
the A or D cells. In addition, NPW mRNA is expressed in the
urogenital system, including the kidney, testis, uterus, ovary, and
placenta (Fujii et al., 2002). Based on RT-PCR analysis, we have
confirmed the presence of NPW mRNA in the pituitary gland,
adrenal gland, and stomach (Seki et al., 2008). These observations
suggest that NPWmay play an important role in the regulation of
the endocrine system in response to stress, as well as in the acti-
vation of the hypothalamus-pituitary-adrenal (HPA) axis (Niimi
and Murao, 2005; Seki et al., 2008).
DISTRIBUTION OF NPBWR1-2
In humans, RT-PCR analysis has demonstrated that NPBWR1
mRNA is highly expressed in the amygdala, hippocampus, neo-
cortex, and hypothalamus (Lee et al., 1999). In situ hybridization
histochemical studies have demonstrated that NPBWR1mRNA is
present in the rat hypothalamus, including the ARC, VMH, PVN,
and DMH, with Ishii et al. (2003) reported that NPBW1 knock-
out mice exhibit hyperphagia and develop adult-onset obesity.
Singh et al. (2004) used [125I]-NPW receptor autoradiography and
demonstrated a significant expression of NPBW1 in the rat amyg-
dala and hypothalamus, as well as in the BST, medial preoptic
area (MPA), PAG, superficial gray layer of the superior colliculus,
and subfornical organ. In general, NPBWR1 is most commonly
expressed at high levels in the amygdala (Singh et al., 2004;
Kitamura et al., 2006; Skrzypski et al., 2012). Although the BST
shows the highest level of NPBWR1 expression in small mam-
mals, this phenomenon has not been demonstrated in humans.
Kitamura et al. (2006) have reported that NPBWR1 is most abun-
dantly expressed in the rat CeA and BST, which may indicate that
NPBWR1 is involved in the regulation of stress, emotion, fear, and
anxiety. On the other hand, NPBWR1-2mRNAs are also localized
in the pituitary and adrenal glands (in both the adrenal cortex
and adrenal medulla) (Mazzocchi et al., 2005). These observa-
tions suggest that NPBWR1-2 may be involved in responding to
stress via the HPA axis (Mazzocchi et al., 2005; Niimi and Murao,
2005). Ziolkowska et al. (2009) recently examined the expres-
sion and function of the NPW, NPB, and NPBWR1 system in
cultured rat calvaria osteoblast-like cells, with their results sug-
gesting a direct effect on this cell proliferation. NPB has been
identified in larger mammals, as well as in rabbits, but has not
been described in either rats or mice. RT-PCR analysis has shown
that NPBWR2 mRNA is highly expressed in the human amyg-
dala, hippocampus, pituitary gland, adrenal gland, and testis, as
well as in the cortical cells in the adrenal gland (Mazzocchi et al.,
2005).
REGULATION OF FEEDING AND ENERGY METABOLISM BY
NPW
NPBWR1 knockout mice are hyperphagic and show decreased
energy expenditure, suggesting that NPW may act as a mod-
ulator of feeding. icv infusion of NPW in male rats has been
shown to increase food intake during the first 2 h in the light
phase (Shimomura et al., 2002). Similarly, Levine et al. (2005)
have reported that injection of NPW into the PVN increases food
intake. These results suggest that NPW acts as an acute orexi-
genic peptide. However, Mondal et al. (2003) have reported that
both forms of NPW suppress dark-phase and fasting-induced
food intake, indicating that the effect of NPW on feeding differs
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depending on whether animals are maintained in a light or dark
phase.
We have carried out a series of neuroanatomical studies to
examine the neural relationship between NPW and other neu-
ropeptides involved in the regulation of feeding. Very close
neuronal interactions were observed between NPW-containing
nerve fibers and orexin- or melanin-concentrating hormone-
containing neuronal cell bodies and nerve fibers in the rat
brain (Takenoya et al., 2005), while Levine et al. (2005) demon-
strated that c-Fos expression was induced in orexin-containing
neurons in the perifornical region of the LH after intracere-
broventricular (icv) infusion of NPW. Interestingly, we also
identified NPW-LI cell bodies in the VMH, which is known
as a center for satiety (Takenoya et al., 2010). Leptin acts
on neurons in the VMH, thereby reducing food intake, and
Date et al. (2010) have recently reported that NPW-LI neu-
rons and leptin receptors are colocalized in this region of the
brain. NPW expression is also significantly up-regulated in
ob/ob and db/db mice. Therefore, NPW may play important
roles in feeding and energy metabolism, functioning as a sub-
stitute for leptin (Date et al., 2010) (Figure 2). Furthermore,
NPW reduces food intake via the melanocortin-4-receptor
signaling pathway, suggesting that it may activate POMC-
containing neurons and inhibit NPY-containing neurons to
control feeding regulation in the ARC (Date et al., 2010)
(Figure 2).
Very recently, Skrzypski et al. (2012) have demonstrated that
NPB and NPW regulate the expression and secretion of lep-
tin and resistin, and increase lipolysis in isolated rat adipocytes.
When NPW was administered to rats, the authors could not
detect enhanced locomotor activity, but did observe increased
O2 consumption and increased CO2 production, as well as an
increase in body temperature (Mondal et al., 2003). Interestingly,
Mondal et al. (2006) have reported that the levels of NPW iso-
lated from rat stomach antral cells are lower in fasted animals,
increasing once the animals have been re-fed. In contrast, female
NPBWR1 −/− mice do not display hyperphagic activity com-
pared with wild-type mice (Ishii et al., 2003). In addition, Dun
et al. (2003) reported the existence of differences between male
and female rats with respect to the distribution of NPW.
NEUROENDOCRINE FUNCTION OF NPW
Immunohistochemical studies have reported that NPBWR1 is
expressed in the PVN, pituitary gland, and adrenal medulla in
the human, mouse and rat (O’Dowd et al., 1995; Lee et al.,
1999; Brezillon et al., 2003; Tanaka et al., 2003), particularly
in the parvocellular subdivisions of the PVN and the posterior
pituitary. However, NPW has not been reported to influence
the release of other anterior pituitary hormones. These neu-
roendocrine effects of NPW are not directly mediated through
NPWBR1 on the pituitary gland cells, but may occur indirectly
through controlling the release of the hypothalamic hormone,
FIGURE 2 | Schematic illustration based on the findings of morphological and physiological studies of appetite regulation in the hypothalamus by
NPW neurons and feeding-related peptides in hypothalamus. The plus or minus indicates stimulatory (+) or inhibitory (−) effects, respectively.
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Table 1 | Physiological effect of NPW in Rat.
Effect References
Food intake ↑ Shimomura et al. (2002), Levine et al. (2005)
↓ Mondal et al. (2003)
Body weight ↑ Tanaka et al. (2003)
Heart rate ↑ Yu et al. (2007a)
Arterial blood
pressure (ABP)
↑ Yu et al. (2007b)
ACTH ↑ Hochol et al. (2007), Yogo et al. (2012)
Prolactin ↑ Baker et al. (2003), Samson et al. (2004)
Growth hormone ↓ Baker et al. (2003), Samson et al. (2004)
Parathyroid hormone ↑ Hochol et al. (2006)
Corticosterome ↑ Baker et al. (2003), Taylor et al. (2005)
Testosterone ↑ Hochol et al. (2006)
Estradiol ↑ Hochol et al. (2006)
The plus or minus indicates stimulatory (↑) or inhibitory (↓) effects, respectively.
corticotrophin-releasing factor (CRF) (Brezillon et al., 2003;
Samson et al., 2004). Colocalization of NPW with urocortin,
a stress-related neuropeptide of the CRF family, has also been
demonstrated in the EW.
On the other hand, icv infusion of NPW23 stimulates pro-
lactin release in the rat (Shimomura et al., 2002), and an in vitro
study has reported that log molar NPW23 concentrations, sig-
nificantly alter prolactin, growth hormone and ACTH release
from dispersed rat anterior pituitary cells (Baker et al., 2003).
In addition, in vivo studies have revealed that icv infusion of
NPW23 stimulates an increase in plasma prolactin levels (Baker
et al., 2003). icv infusion of NPW23 also results in a significant,
elevation in plasma corticosterone levels, suggesting that NPW
plays a role in the hypothalamic response to stress. However,
growth hormone levels in plasma are inhibited by icv infu-
sion of this peptide. These findings suggest that NPW is the
endogenous ligand for GPR7 and/or GPR8 and acts as a media-
tor of neuroendocrine function (Shimomura et al., 2002; Baker
et al., 2003). Moreover, Taylor et al. (2005) have reported that
the infusion of NPW activates the HPA axis, as demonstrated
by changes in plasma corticosterone levels in conscious rats;
NPW increases plasma corticosterone levels but does not stim-
ulate the release of oxytocin or vasopressin in the peripheral
circulation, or alter blood pressure or heart rate. Furthermore,
icv infusion of a CRF antagonist does not significantly reduce
corticosterone levels, although CRF antagonist pretreatment sig-
nificantly reduces the capacity of centrally administered NPW to
increase corticosterone levels (Taylor et al., 2005). Using electro-
physiological studies with whole-cell patch recording of hypotha-
lamic slice preparations, Taylor et al. (2005) have also shown
that NPW depolarizes and increases the spike frequency of the
majority of putative neuroendocrine PVN neurons. Furthermore,
the response of these cells in the presence of tetrodotoxin con-
firmed that NPW was acting post-synaptically (Taylor et al.,
2005).
Niimi andMurao (2005) have reported that double immunos-
taining for both NPW and c-Fos is significantly increased in
response to stress. Immobilization stress increases parasympa-
thetic outflow, whereas cold stress is primarily considered to
increase sympathetic outflow, suggesting that NPW may partic-
ipate in the regulation of both the sympathetic and parasympa-
thetic branches of the autonomic nervous system. In the PVN,
vasopressin- expressing neurons are known to be involved in
the production of hormonal outputs in response to endocrine
and autonomic stress (Ulrich-Lai and Herman, 2009). Kawasaki
et al. (2006) have reported that centrally administered NPW
activates magnocellular neurosecretory neurons in the SO and
PVN, and significantly increases plasma arginine-vasopressin and
plasma oxytocin levels. Price et al. (2008) have reported that
the inhibition of growth hormone release due to the central
effects of NPW results from activation of arcuate somatostatin
neurons, which could produce inhibition of neurons express-
ing growth hormone releasing hormone. These findings sug-
gest that endogenous NPW may play a physiologically rele-
vant role in the neuroendocrine response to stress in the brain
(Table 1).
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